Advair Vs. Symbicort

Featured Article

Have questions or comments? Click here.

Last week the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs). The advisory panel consisted of 27 voting health care professionals representing subcommittees in pulmonary and allergy medicine, safety and risk, and pediatric advisory.

The medications of interest were LABAs prescribed for treatment... Read more

More information on "Advair Vs. Symbicort"

From Our Experts

See more SharePosts »